Cerebral Creatine Deficiency Syndromes: Clinical Aspects, Treatment and Pathophysiology
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Cerebral creatine deficiency syndromes (CCDSs) are a group of inborn errors of creatine metabolism comprising two autosomal recessive disorders that affect the biosynthesis of creatine--i.e. arginine:glycine amidinotransferase deficiency (AGAT; MIM 602360) and guanidinoacetate methyltransferase deficiency (GAMT; MIM 601240)--and an X-linked defect that affects the creatine transporter, SLC6A8 deficiency (SLC6A8; MIM 300036). The biochemical hallmarks of these disorders include cerebral creatine deficiency as detected in vivo by 1H magnetic resonance spectroscopy (MRS) of the brain, and specific disturbances in metabolites of creatine metabolism in body fluids. In urine and plasma, abnormal guanidinoacetic acid (GAA) levels are found in AGAT deficiency (reduced GAA) and in GAMT deficiency (increased GAA). In urine of males with SLC6A8 deficiency, an increased creatine/creatinine ratio is detected. The common clinical presentation in CCDS includes mental retardation, expressive speech and language delay, autistic like behaviour and epilepsy. Treatment of the creatine biosynthesis defects has yielded clinical improvement, while for creatine transporter deficiency, successful treatment strategies still need to be discovered. CCDSs may be responsible for a considerable fraction of children and adults affected with mental retardation of unknown etiology. Thus, screening for this group of disorders should be included in the differential diagnosis of this population. In this review, also the importance of CCDSs for the unravelling of the (patho)physiology of cerebral creatine metabolism is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since that time, several additional case reports and reviews have been published, highlighting effective strategies to diagnose and treat cerebral creatine deficiency with consistent improvements in intellectual development reported, especially when early detection and ensuing treatment were employed [51,52].”
From Creatine Supplementation in Children and Adolescents (2021) · cites this paper as [51]
In the citing paper
“Several studies and case reports have indicated that creatine supplementation can restore tissue creatine content and improve some of the symptoms resulting from creatine deficiencies [51,52,53,54].”
From Creatine Supplementation in Children and Adolescents (2021) · cites this paper as [51]
In the citing paper
“Since its discovery in 1994, GAMT deficiency has shown to be treatable through creatine supplementation strategies [51,53].”
From Creatine Supplementation in Children and Adolescents (2021) · cites this paper as [51]
In the citing paper
“Although similar, creatine transporter deficiency is another inborn error of metabolism that can result in creatine deficiencies in select tissues, particularly within the brain [51].”
From Creatine Supplementation in Children and Adolescents (2021) · cites this paper as [51]
In the citing paper
“Moreover, creatine transporter 1 (CrT1) is expressed ubiquitously across human tissues and deficiencies of this protein are another type of creatine metabolism disorder that can result in brain atrophy, intellectual disabilities, and developmental delays [51].”
From Creatine Supplementation in Children and Adolescents (2021) · cites this paper as [51]
Citations
Cites
Creatine and Creatinine Metabolism
Wyss, M., & Kaddurah-Daouk, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.1107 · Cited by 2,950 · cited 4×
“GAA is a known competitive inhibitor of the creatine transporter and is thought to be taken up via the SLC6A8 transporter (Wyss and Kaddurah-Daouk, 2000).”
BackgroundInfluentialVolpe, J. J. (1981) · PubMed · Cited by 2,932
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682 · cited 2×
“animal models of various neurodegenerative diseases (Brewer and Wallimann, 2000; Klivenyi et al., 1999; Matthews et al., 1998, 1999).”
BackgroundCreatine: Biosynthesis, Regulation, and Function
Walker, J. B. (1979) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470122952.ch4 · Cited by 496 · cited 1×
“This reaction is catalyzed by S-adenosyl-L-methionine:N -guanidinoacetate methyltransferase (GAMT) (Walker, 1979; Wyss and Kaddurah-Daouk, 2000).”
Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease
Matthews, R. T., Yang, L., Jenkins, B. G., Ferrante, R. J., Rosen, B. R., Kaddurah-Daouk, R., & Beal, M. F. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-01-00156.1998 · Cited by 430 · cited 1×
“This has been shown in neuronal cultures during exposure to high glutamate concentrations and in animal models of various neurodegenerative diseases (Brewer and Wallimann, 2000; Klivenyi et al., 1999; Matthews et al., 1998, 1999).”
BackgroundCreatine deficiency in the brain: A new, treatable inborn error of metabolism
Stöckler, S., Holzbach, U., Hanefeld, F., Marquardt, I., Helms, G., Requart, M., Hänicke, W., & Frahm, J. (1994) · Pediatric Research · doi:10.1203/00006450-199409000-00023 · Cited by 417 · cited 1×
“GAMT deficiency was the first CCDS to be recognized in humans in 1994 (Stöckler et al., 1994).”
BackgroundSelf-citationX-Linked Creatine-Transporter Gene (SLC6A8) Defect: A New Creatine-Deficiency Syndrome
Salomons, G. S., van Dooren, S. J. M., Verhoeven, N. M., Cecil, K. M., Ball, W. S., Degrauw, T. J., & Jakobs, C. (2001) · The American Journal of Human Genetics · doi:10.1086/320595 · Cited by 396 · cited 1×
“This hypothesis was confirmed by demonstration of deficient creatine uptake in fibroblasts and by identification of a hemizygous mutation in the SLC6A8 gene mapped to the X chromosome (Salomons et al., 2001).”
BackgroundInborn Metabolic Diseases: Diagnosis and Treatment
(2012) · doi:10.1007/978-3-642-15720-2 · Cited by 377
Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity
Matthews, R. T., Ferrante, R. J., Klivenyi, P., Yang, L., Klein, A. M., Mueller, G., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7049 · Cited by 373 · cited 2×
“animal models of various neurodegenerative diseases (Brewer and Wallimann, 2000; Klivenyi et al., 1999; Matthews et al., 1998, 1999 ).”
BackgroundStöckler, S., Hanefeld, F., & Frahm, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04116-5 · Cited by 240 · cited 3×
“Subsequent studies confirmed the absence of GAMT activity in liver and identified the pathogenic mutations in the GAMT gene (Stöckler et al., 1996b).”
BackgroundSelf-citation
Research works printed but not linked: 1
- De Vries, M., Morava, E., Rodenburg, R., Kluijtmans, L., Verhoeven, N.M., Salomons, G.S., Jakobs, C., and Smeitink, J., 2005, Mitochondrial dysfunction in creatine biosynthesis disorder. J. Inherit. Metab. Dis. 28: 227.
Cited by
Functions and effects of creatine in the central nervous system
Andres, R. H., Ducray, A. D., Schlattner, U., Wallimann, T., & Widmer, H. R. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.02.035 · Cited by 368
van Karnebeek, C. D. M., & Stockler, S. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.11.191 · Cited by 212
“Arguably, the incidence of the individual 81 conditions is low, ranging from 1:10,000 to less than 1:200,000 [53].”
BackgroundSynthesis and transport of creatine in the CNS: Importance for cerebral functions
Béard, E., & Braissant, O. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06935.x · Cited by 192
“mental retardation, delays in speech acquisition or epilepsy (Stöckler et al. 2007).”
BackgroundInfluentialCreatine Supplementation and Brain Health
Roschel, H., Gualano, B., Ostojic, S. M., & Rawson, E. S. (2021) · Nutrients · doi:10.3390/nu13020586 · Cited by 174
Creatine deficiency syndromes and the importance of creatine synthesis in the brain
Braissant, O., Henry, H., Béard, E., & Uldry, J. (2011) · Amino Acids · doi:10.1007/s00726-011-0852-z · Cited by 145
“With the exception of SLC6A8-deficient heterozygous females where brain Cr deficiency is partial (Cecil et al. 2003), all three Cr deficiencies present the virtual absence of the Cr peak measured by MRS in cortex and basal ganglia (Stöckler et al. 2007).”
BackgroundMethodInfluential
Metadata
- Authors
- Stockler, S., Schutz, P. W., & Salomons, G. S.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- ORCID
- Salomons, Gajja S.
- Venue
- Subcellular Biochemistry
- Publisher
- Springer Netherlands
- Published
- 2007-10-15
- Volume
- 46
- Pages
- 149-166
- OpenAlex
- W185449676
- Cited by
- 180
- References
- 66
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 7 · 2023: 14 · 2022: 5 · 2021: 8 · 2020: 2 · 2019: 4 · 2018: 7 · 2016: 9 · 2015: 13 · 2014: 18 · 2013: 12 · 2012: 13
- FWCI
- 41.92
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Springer eBooks (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- cerebral creatine deficiency syndrome, guanidinoacetate methyltransferase deficiency, creatine transporter deficiency, guanidinoacetic acid, 1H magnetic resonance spectroscopy, intellectual disability, epilepsy, autism-like behavior, creatine synthesis, differential diagnosis, screening
- MeSH terms
- Adult, Amidinotransferases, Animals, Cerebellar Diseases, Child, Child, Preschool, Creatine, Creatinine, Diagnosis, Differential, Female, Glycine, Humans, Male, Nerve Tissue Proteins, Syndrome, Brain Diseases, Metabolic, Inborn, Genetic Diseases, X-Linked, Plasma Membrane Neurotransmitter Transport Proteins, Guanidinoacetate N-Methyltransferase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cerebral Creatine Deficiency Syndromes: Clinical Aspects, Treatment and Pathophysiology. https://app.cochat.ai/papers/10.1007/978-1-4020-6486-9_8
- The paper
- Stockler, S., Schutz, P. W., & Salomons, G. S. (2007). Cerebral Creatine Deficiency Syndromes: Clinical Aspects, Treatment and Pathophysiology. Subcellular Biochemistry. https://doi.org/10.1007/978-1-4020-6486-9_8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.